← GLP-1 receptor agonists × body weight & composition

SynthesisJournal of diabetes2025

Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis.

Yucheng Yang et al.PubMed ↗Full text ↗Publisher ↗

  • GLP-1RAslooks bad hereHigher weight reduction.Weak evidence: one subgroup.
  • Dulaglutidelooks bad hereHigher weight reduction.Weak evidence: one subgroup.
  • Semaglutidelooks bad hereHigher weight reduction.Weak evidence: one subgroup.

What the trial testedrandomised · 2025

One subgroup

May have raised weight reduction in females

+1.04kg+0.70 to +1.38

GLP-1RAs vs placebo, in females

As reported

difference 1.04 kg, 95% CI 0.70–1.38

One subgroup

May have raised weight reduction in females

+1.69percentage points+0.78 to +2.61

GLP-1RAs vs placebo, in females

As reported

difference 1.69 %, 95% CI 0.78–2.61

One subgroup

May have raised weight reduction in overall

+0.88kg+0.67 to +1.09

GLP-1RAs vs placebo, in overall

As reported

difference 0.88 kg, 95% CI 0.67–1.09

One subgroup

May have raised weight reduction in indications for weight reduction

+4.21kg+1.75 to +6.67

GLP-1RAs vs placebo, in indications for weight reduction

As reported

difference 4.21 kg, 95% CI 1.75–6.67

+2 more in the walkthrough ↓

Who was studied, and how

people with type 2 diabetes, in this paper

Among females, the trial randomly assignedassigned by chance

GLP-1RAs
placebo

May have raised weight reduction+1.04

randomised · one subgroup

Among overall, the trial randomly assignedassigned by chance

GLP-1RAs
placebo

May have raised weight reduction+0.88

randomised · one subgroup

the abstract, start to end

… females lost more weight than males (MD 1.04 kg [95% CIs 0.70-1.38]; MD 1.69% [95% CI 0.78-2.61]).

… GLP-1RAs indicated similar results (MD 0.88 kg [95% CIs 0.67-1.09]).

… difference in weight reduction (MD 4.21 kg [95% CIs 1.75-6.67]).

Dulaglutide (MD 0.88 kg [95% CIs 0.63-1.12]) and semaglutide (MD 1.04 kg [95% CIs 0.45-1.63]) showed …

← favours treatmentfavours comparator →
could be chance
Weight reductionGLP-1RAs vs placebo, in females
1.040.70–1.38
Weight reductionGLP-1RAs vs placebo, in females
1.690.78–2.61
Weight reductionGLP-1RAs vs placebo, in overall
0.880.67–1.09
Weight reductionGLP-1RAs vs placebo, in indications for weight reduction
4.211.75–6.67
Weight reductiondulaglutide vs placebo, in dulaglutide
0.880.63–1.12
Weight reductionsemaglutide vs placebo, in semaglutide
1.040.45–1.63
GLP-1 receptor agonistsBody weight & composition

GLP-1 receptor agonists × body weight & compositionhelps?replicated

unlikelylikely
0.90not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 6

36 papers cite it

2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 40040445